Soligenix (OTC: SNGX) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

60.2% of Mirati Therapeutics shares are owned by institutional investors. 5.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Soligenix and Mirati Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Soligenix $9.15 million N/A -$5.45 million N/A N/A
Mirati Therapeutics N/A N/A -$73.47 million ($3.43) -3.88

Soligenix has higher revenue and earnings than Mirati Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Soligenix and Mirati Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 0 0 2 0 3.00
Mirati Therapeutics 0 3 7 0 2.70

Soligenix currently has a consensus target price of $8.00, suggesting a potential upside of 250.88%. Mirati Therapeutics has a consensus target price of $12.63, suggesting a potential downside of 5.08%. Given Soligenix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Soligenix is more favorable than Mirati Therapeutics.

Profitability

This table compares Soligenix and Mirati Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix -233.27% -196.47% -122.14%
Mirati Therapeutics N/A -101.85% -86.50%

Summary

Mirati Therapeutics beats Soligenix on 6 of the 10 factors compared between the two stocks.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings for Soligenix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.